A 15-year-old boy with a severe genetic form of epilepsy walked on his own for the first time after receiving a custom-built antisense oligonucleotide designed to silence only the mutant copy of his SCN2A gene. A second boy, age 9, saw his seizure frequency drop by 26 percent over roughly two years of treatment. The two cases, run as parallel single-patient clinical studies at UC San Diego, represent the clearest evidence yet that individually manufactured gene therapies can produce measurable neurological gains in children whose conditions have no approved drug.
Why custom SCN2A therapy changes the calculus for rare epilepsy
SCN2A mutations cause developmental epileptic encephalopathy, a condition that typically resists standard anti-seizure medications and leaves many patients unable to walk, speak, or feed themselves. The two boys treated in these trials carried gain-of-function mutations, meaning their defective gene copy was overactive and toxic to developing brain circuits. Conventional drugs can blunt seizure activity but do nothing to address the root genetic problem, so families face decades of emergency-room visits, intensive therapies, and round-the-clock care.
The antisense oligonucleotides used in these cases were designed to reduce the mutant SCN2A transcript while preserving the healthy, wild-type copy, according to the Nature Medicine paper reporting the results. That allele-selective strategy matters because SCN2A encodes a sodium channel protein the brain needs in precise amounts. Knocking down both copies would risk new problems; targeting only the harmful variant aims to restore a closer-to-normal balance.
The older patient’s response was dramatic. After treatment, his seizure burden fell by 90 percent and he achieved independent walking at age 15, a milestone his family and clinicians had considered unlikely. The younger child’s 26 percent seizure reduction was more modest but still statistically meaningful as a primary endpoint, given that his baseline seizure rate had been resistant to multiple prior medications.
Two-year trial data and the regulatory path from milasen to SCN2A
Both single-patient studies ran for approximately two years and are formally registered as a clinical investigation focused on personalized antisense therapy. The primary endpoint was change in seizure frequency, with secondary measures tracking developmental and motor gains. Investigators monitored seizure counts, caregiver diaries, and neurologic assessments to determine whether the experimental ASOs altered the course of disease beyond day-to-day variability.
Funding came in part from the California Institute for Regenerative Medicine, which describes the project as a personalized antisense therapy for a rare pediatric SCN2A disorder under award CLIN2-15085. That state grant helped make the individualized manufacturing process financially feasible for a therapy that, by definition, has a market size of one. Without such support, the cost of designing, testing, and producing a clinical-grade batch for a single child would likely be beyond the reach of most families and academic centers.
The scientific lineage traces back to milasen, a one-patient antisense oligonucleotide created for a child with Batten disease and described in a 2019 New England Journal report. That earlier effort established a regulatory and manufacturing template: identify the patient’s exact mutation, design and test an ASO against it in cell and animal models, produce a clinical-grade batch, and administer it under a single-patient investigational framework. The SCN2A team at UC San Diego built on that playbook but added the allele-selective twist, which required distinguishing between two nearly identical gene copies at the molecular level.
The 90 percent seizure reduction in the older boy and the fact that he gained a major motor skill suggest the therapy did more than suppress electrical storms. It may have allowed developmental circuits to function in ways they had not been able to before, though the Nature Medicine authors stopped short of claiming structural brain recovery. The 26 percent reduction in the younger child, while smaller, still exceeded what most standard medications had achieved for him and met the prespecified threshold for clinical benefit in this ultra-rare context.
Across both cases, safety signals were closely watched. The children received repeated intrathecal injections, the same route used for other approved antisense drugs, and were followed for signs of inflammation, off-target neurologic effects, and systemic toxicity. Within the two-year window, the investigators reported no dose-limiting toxicities, but the small sample size and limited follow-up mean rare or delayed adverse events cannot yet be ruled out.
Unanswered questions about durability, cost, and scale
Two patients over two years is enough to demonstrate biological proof of concept but not enough to establish long-term safety or predict how the therapy will perform across the broader SCN2A patient population. No public data yet detail immunogenicity responses beyond the trial window, and raw seizure-count logs and EEG metrics beyond the aggregated percentages have not been released. Whether the seizure reductions will hold at three, five, or ten years is unknown, and the possibility that repeated dosing could eventually trigger immune reactions remains an open concern.
There is also uncertainty about how early in life such a therapy must be given to maximize benefit. The older boy’s ability to walk for the first time at 15 suggests that some neural circuits retain plasticity well into adolescence, but it is unclear whether treating infants or toddlers with the same mutation would yield even larger developmental gains. Conversely, intervening too early, before clinicians fully understand a child’s trajectory, could expose very young patients to risks that are still being characterized.
Cost is another unresolved issue. Manufacturing a single batch of a custom ASO requires molecular design, preclinical validation, and sterile production, all for one patient. The CIRM grant under award CLIN2-15085 covered a portion of those expenses, but no public filings break out the full per-patient cost. If allele-selective ASOs prove durable, families and insurers will need to weigh a large upfront investment against decades of avoided hospitalizations, emergency interventions, and full-time care. A reasonable hypothesis is that sustained seizure control could cut lifetime medical spending substantially, but that claim will require years of follow-up claims data to test.
Ethical questions accompany the economic ones. When a therapy is engineered for a single child, traditional notions of equitable access and fair pricing become harder to apply. Families with the resources and connections to assemble scientific teams and navigate regulatory pathways may reach experimental treatments faster than others with the same mutations. Public and philanthropic funders will be pressed to decide how many one-off therapies they can support and how to prioritize among competing ultra-rare conditions.
The next concrete development to watch is whether the UC San Diego team expands enrollment to additional SCN2A patients or whether other centers adopt the same allele-selective design framework for different epilepsy genes. Regulatory agencies have not yet signaled how they will evaluate therapies built for a single person, and payers have no established reimbursement model for drugs with a market of one. For the moment, the SCN2A experience stands as both a technical milestone and a test case: it shows that precisely targeted antisense drugs can change the lives of individual children, while underscoring how much work remains to turn bespoke genetic medicines into a sustainable, broadly accessible part of neurological care.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
